Drug Profile
Research programme: glial cell-derived neurotrophic factor - Eli Lilly and Company
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; Medtronic
- Class Nerve growth factors
- Mechanism of Action Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Parkinson's-disease in USA (Parenteral, Implant)
- 26 Apr 2011 Early research in Parkinson's disease in USA (Parenteral)